Abstract：Objective To investigate the effect of O-6-methylguananine-DNA methyltransferase (MGMT) gene promoter methylation status on the treatment and prognosis of elderly patients newly-diagnosed with glioblastoma (GBM). Methods Clinical data of 65 newly-diagnosed GBM patients admitted to Tianjin Huanhu Hospital from January 2012 to December 2018 were retrospectively analyzed. All patients received intensity-modulated radiotherapy after surgery and 49 patients received temozolomide (TMZ) monotherapy. All patients were divided into the MGMT(+) group and MGMT(-) group according to the methylation status of MGMT promoter. Kaplan-Meier method and log-rank test were used for univariate survival analysis, and Cox regression model was used for multivariate prognostic analysis. Results The median overall survival (OS) for all patients was 18.0 months. The median OS was 27.0 months and 15.3 months in the MGMT(+) group and MGMT(-) group, respectively. Univariate analysis revealed that tumor number, MGMT promoter methylation, postoperative concurrent chemoradiotherapy were significantly related to clinical prognosis (P=0.029, P=0.001 and P<0.001). In multivariate analysis, tumor number and postoperative concurrent chemoradiotherapy were identified as significant prognostic factors for OS (P=0.037,P=0.004). In the MGMT(+) group, the median OS was 27.0 months for patients receiving concurrent chemoradiotherapy and 12.0 months for radiotherapy alone (P=0.040). In the MGMT(-) group, the median OS was 17.0 months for concurrent chemoradiotherapy patients and 10.0 months for radiotherapy alone (P=0.122). Conclusions MGMT promoter methylation status is significantly associated with longer OS in elderly GBM patients. Conventional fractional radiotherapy combined with concurrent and sequential TMZ chemotherapy probably yields better survival benefits.
Sun Yafang,Wang Zheng,Shi Xiangyu et al. Effect of MGMT gene methylation status on chemoradiotherapy and prognosis in elderly patients with glioblastoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 446-450.
[1] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2007-2011[J]. Neuro Oncol, 2014, 16(Suppl 4):iv1-iv63. DOI:10.1093/neuonc/nou223. [2] Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma:a meta-analysis of clinical trials[J]. J Cell Physiol, 2018, 233(1):378-386. DOI:10.1002/jcp.25896. [3] Villani V, Tanzilli A, Telera SM, et al. Comorbidities in elderly patients with glioblastoma:a field-practice study[J]. Future Oncol, 2019, 15(8):841-850. DOI:10.2217/fon-2018-0524. [4] Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma:the Nordic randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(9):916-926. DOI:10.1016/S1470-2045(12)70265-6. [5] Perry JR, Laperriere N, O′Callaghan CJ, et al. Short-Course radiation plus temozolomide in elderly patients with glioblastoma[J]. N Engl J Med, 2017, 376(11):1027-1037. DOI:10.1056/NEJMoa1611977. [6] Scott J, Tsai YY, Chinnaiyan P, et al. Effectiveness of radiotherapy for elderly patients with glioblastoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1):206-210. DOI:10.1016/j.ijrobp.2010.04.033. [7] Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly:the NOA-08 randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(7):707-715. DOI:10.1016/S1470-2045(12)70164-X. [8] Bracci S, Laigle-Donadey F, Hitchcock K, et al. Role of irradiation for patients over 80 years old with glioblastoma:a retrospective cohort study[J]. J Neurooncol, 2016, 129(2):347-353. DOI:10.1007/s11060-016-2182-1. [9] Uzuka T, Asano K, Sasajima T, et al. Treatment outcomes in glioblastoma patients aged 76 years or older:a multicenter retrospective cohort study[J]. J Neurooncol, 2014, 116(2):299-306. DOI:10.1007/s11060-013-1291-3. [10] 国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志,2019, 35(3):217-239. DOI:10.3760/cma.j.issn.1001-2346.2019.03.001. Medical ADministration and Medical Authority, National Health Commission. Practice for the diagnosis and treatment of glioma (2018 Edition)[J]. Chin J Neurosurg, 2019, 35(3):217-239. DOI:10.3760/cma.j.issn.1001-2346.2019.03.001. [11] Noorbakhsh A, Tang JA, Marcus LP, et al. Gross-total resection outcomes in an elderly population with glioblastoma:a SEER-based analysis[J]. J Neurosurg, 2014, 120(1):31-39. DOI:10.3171/2013.9. JNS13877. [12] Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older[J]. Cancer, 2012, 118(22):5595-5600. DOI:10.1002/cncr.27570. [13] Marko NF, Weil RJ, Schroeder JL, et al. Extent of resection of glioblastoma revisited:personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery[J]. J Clin Oncol, 2014, 32(8):774-782. DOI:10.1200/JCO.2013.51.8886. [14] 刘竞辉,娄淼,冀培刚,等. 老年胶质瘤预后相关因素分析[J]. 中南大学学报(医学版),2018, 43(4):403-409. DOI:10.11817/j.issn.1672-7347.2018.04.011. Liu JH, Lou M, Ji PG, et al. Analysis of prognostic factors for survival in elderly patients with glioma[J]. J Cent South Univ (Med Sci), 2018, 43(4):403-409. DOI:10.11817.j.issn.1672-7347.2018.04.011. [15] Heiland DH, Haaker G, Watzlawick R, et al. One decade of glioblastoma multiforme surgery in 342 elderly patients:what have we learned?[J]. J Neurooncol, 2018, 140(2):385-391. DOI:10.1007/s11060-018-2964-8. [16] 王艳敏,段文超,王伟伟,等. 老年胶质母细胞瘤患者预后影响因素分析[J]. 中华医学杂志,2020, 100(2):121-124. DOI:10.3760/cma.j.issn.0376 2491.2020.02.008. Wang YM, Duan WC, Wang WW, et al. Analysis of clinical, pathological features and therapeutic treatments in predicting prognosis of elderly glioblastomas[J]. Natl Med J China, 2020, 100(2):121-124. DOI:10.3760/cma.j.issn.0376 2491.2020.02.008. [17] Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly[J]. Int J Cancer, 2012, 131(6):1342-1350. DOI:10.1002/ijc.27385. [18] Bozdag S, Li A, Riddick G, et al. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels[J]. PLoS One, 2013, 8(4):e62982. DOI:10.1371/journal.pone.0062982. [19] Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide[J]. J Neurooncol, 2011, 102(2):311-316. DOI:10.1007/s11060-010-0324-4. [20] Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(11):1537-1570. DOI:10.6004/jnccn.2020.0052.
2021, Vol. 30 
